Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors

Park, Yeon Hee; Lam, Ka-On; Law, Ada; Lee, C Cy; Chiang, Chi Leung; Au, K H; Mo, Frankie; So, Tsz Him; Lam, K. C.; Ng, Wai Tong; Li, L

doi:10.12809/hkmj164885

Cited by 4 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ACTS-GC trial showed that the compliance of 1-year S-1 completion is only 65.8%, and the patients with non-continuation experienced tumor recurrence or intolerance to AEs (5,6). This finding was also reported by other real-world adjuvant S-1 studies, with similar completion rates for 1-year S-1 ranging from 59% to 69%, including studies from Japan, Korea, and Hong Kong (24)(25)(26). Moreover, the dose reduction rate is another issue.…”

Section: Discussionsupporting

confidence: 61%

“…Moreover, the dose reduction rate is another issue. In the ACTS-GC trial, 42.4% of patients with GC had adjuvant S-1 treatment with dose reduction; in addition, the dose reduction rate was high at up to 73.3% of all patients with GC in a Hong Kong study and 31% of patients with GC who completed 1-year S-1 treatment (5,24,26). In contrast, a Japanese study showed that there was a significantly higher 1-year completion rate and a lower percentage of grade 3-4 AEs for stage II or III patients with GC who were administered S-1 as adjuvant treatment for 2 weeks, followed by a 1-week rest, compared to those with S-1 administration for 4 weeks, followed by a 2-week rest (13).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients

Liu¹,

Liu²,

Chen³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: This study aimed to investigate the clinical outcome of adjuvant S-1 with 2-week administration followed by a 1-week rest for locally advanced gastric cancer (GC) patients. Methods:The current study was a single retrospective cohort study that focused on the efficacy and toxicity of adjuvant S-1 with a 3-week schedule. A total of 60 patients who underwent total or subtotal gastrectomy plus D2 lymph node dissection and adjuvant S-1 treatment were identified. S-1 treatment began within 4 weeks after the operation; it was administered orally for 2 weeks, followed by a 1-week rest. The dose of S-1 was adjusted depending on adverse events (AEs), with at least 80 mg administered daily. The completion of 1-year S-1 was defined as S-1 continuation for 1 year with over 70% of the planned dose.Patients were followed up with for 5 years postoperatively and underwent hematologic tests and assessments of clinical symptoms every 3-6 weeks for 1 year after surgery. Computed tomography of the abdomen and panendoscopy were performed every 6 months during the first 2 years and at 1-year intervals thereafter until year 5 after surgery. Results:The completion rate of 1-year adjuvant S-1 was 71.7%, and the 3-year disease-free survival and overall survival rates were 70.2% and 79.5%, respectively. Seventeen patients did not complete S-1 for 1 year, including 11 patients with tumor recurrence and 6 patients who developed intolerance. Most AEs of S-1 were grade 1-2, and the most frequent AEs (>20%) included anemia, fatigue, pigmentation, nausea, and diarrhea. The most common grade 3-4 AE was fatigue, which was observed in 6.7% of patients. Most patients tolerated the side effects. Conclusions:The results of our study confirm that the efficacy and safety of schedule modification of adjuvant S-1 treatment in patients with GC who underwent gastrectomy with D2 lymph node dissection are equal to those in a previous phase 3 study.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients

Liu¹,

Liu²,

Chen³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Indirect costs were patients’ time and transportation costs. Costs of chemotherapy, anti-EGFR mAb and bevacizumab were based on the weight or body surface area according to the medication indication ( 26 ). Grade 3 or above AEs were included in the model, which composed of acneiform rash, diarrhea, infection, leukopenia, and neutropenia.…”

Section: Methodsmentioning

confidence: 99%

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer

et al. 2021

View full text Add to dashboard Cite

ObjectivesWe aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-line treatment in KRAS wild-type (WT), pan-RAS WT and pan-RAS WT left-sided metastatic colorectal cancer (mCRC) patients from the Hong Kong societal perspective.Materials and MethodsWe developed Markov models and 10-year horizon to estimate costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of chemotherapy plus anti-EGFR therapy against chemotherapy plus Bev in KRAS WT, pan-RAS WT, and pan-RAS WT left-sided mCRC. We considered two times of the local gross domestic product per capita (GDPpc) as the willingness-to-pay (WTP) threshold (2× GDPpc; US$97,832).ResultsAdding anti-EGFR mAb to chemotherapy provides additional 0.24 (95% confidence interval [CI] 0.19–0.29), 0.32 (95% CI 0.27–0.37), and 0.57 (95% CI 0.49–0.63) QALY compared to adding Bev in KRAS WT, pan-RAS WT, and left-sided pan-RAS WT mCRC populations respectively. The corresponding ICER is US$106,847 (95% CI 87,806–134,523), US$88,565 (95% CI 75,678–105,871), US$76,537 (95% CI 67,794–87,917) per QALY gained, respectively.ConclusionsAnti-EGFR therapy is more cost-effective than Bev as a first-line targeted therapy in left-sided pan-RAS WT and pan-RAS WT, with ICER <US$100,000/QALY, compared to KRAS WT mCRC population.

show abstract

“…S-1 that is composed of the three drugs can prolong and maintain 5-Fu concentration and reduce its toxicity (19). This drug is common for the treatment of various tumor diseases including SC (20)(21)(22). PC, an interdisciplinary specialty, is dedicated to improving the QOL of critically ill patients and their families through symptom management, communication, and patient autonomy (23).…”

Section: ------------------------------------------------------------------------------------Groupsmentioning

confidence: 99%

Effects of S‑1 combined with palliative care on immune function and quality of life of patients with advanced stomach cancer

Wang

2020

Oncol Lett

View full text Add to dashboard Cite

The present study aimed to investigate the effects of S-1 combined with palliative care (PC) on the immune function and quality of life (QOL) of patients with advanced stomach cancer (ASC). In this prospective study, 168 patients with ASC admitted to our hospital from September 2016 to March 2018 were enrolled as research objects. Seventy-seven cases were treated with S-1 alone (single drug group, SDG), while another 91 cases were treated with S-1 combined with PC (combined drug group, CDG). The effects of the two therapeutic methods on the efficacy [overall response rate (ORR)], 1-year overall survival rate (OSR), safety, negative emotions, nutritional indices, QOL, and immune function indices of patients were analyzed. After treatment, ORR, OSR, levels of nutritional indices [albumin (ALB), prealbumin (PA), and transferrin (TF)], and QOL improvement rate in the CDG were significantly higher than those in the SDG (P<0.05). After treatment, compared with those in the SDG, patients in the CDG had a lower Self-Rating Anxiety Scale (SAS) score, Self-Rating Depression Scale (SDS) score, and number of adverse reactions (P<0.05), and significantly improved immune function indices (CD4 + , CD8 + , and CD4 + /CD8 + ) (P<0.05). S-1 combined with PC treatment was superior to S-1 treatment alone in patients with ASC. The patients treated with the combination exhibited improved efficacy (a higher ORR), higher QOL, and improved immune function, and thus this treatment can be clinically popularized.

show abstract

Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors

Cited by 4 publications

References 12 publications

The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients

The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer

Effects of S‑1 combined with palliative care on immune function and quality of life of patients with advanced stomach cancer

Contact Info

Product

Resources

About